Add-on Acquisition • Life Science

Athenex Acquires Kuur Therapeutics

On May 4, 2021, Athenex acquired life science company Kuur Therapeutics for 185M USD

Acquisition Context

This is Athenex’s 2nd transaction in the Life Science sector.
This is Athenex’s largest (disclosed) transaction.
This is Athenex’s 1st transaction in the United Kingdom.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	May 4, 2021
Target	Kuur Therapeutics
Sector	Life Science
Buyer(s)	Athenex
Deal Type	Add-on Acquisition
Deal Value	185M USD

Target Company

Kuur Therapeutics

London, United Kingdom

Kuur Therapeutics is a developer, manufacturer, and marketer of cellular immunotherapy products for the treatment of cancer and infections. Kuur Therapeutics’s lead oncology product, baltaleucel-T, is aimed at a range of cancers associated with the oncogenic Epstein Barr virus (EBV), including non-Hodgkin lymphomas, Hodgkin lymphoma, and nasopharyngeal carcinoma. Kuur Therapeutics is based in London, United Kingdom.

Explore More Deals

Browse All 215,158 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Athenex

Buffalo, New York, United States

Category	Company
Founded	2003
Sector	Life Science
Employees	652
Revenue	120M USD (2021)

DESCRIPTION

Athenex is a global biopharmaceutical company dedicated to discovery, development, and commercialization of novel therapies for the treatment of cancer. Athenex was founded in 2003 and is based in Buffalo, New york.

Deal Context for Buyer	#
Overall	2 of 2
Sector: Life Science	2 of 2
Type: Add-on Acquisition	2 of 2
Country: United Kingdom	1 of 1
Year: 2021	1 of 1
Size (of disclosed)	1 of 1

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2014-09-09	QuaDPharma New York, New York, United States QuaDPharma specializing in pharmaceutical manufacturing, analytical, and support services to the pharmaceutical and biotech industries.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2014-09-09

QuaDPharma

New York, New York, United States

QuaDPharma specializing in pharmaceutical manufacturing, analytical, and support services to the pharmaceutical and biotech industries.

Buy

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - United Kingdom M&A - 2021 M&A